Regarding the NanoLogix "Non-Comprehensive" Update
Post# of 9144
Posted On: 06/07/2016 12:47:46 PM
Regarding the NanoLogix "Non-Comprehensive" Update.
I just had the chance to look at the recent update. It strikes me as quite a positive outlook but I wanted to set out several of the most exciting aspects. First, for those who have not actually read it I am copying some of the text immediately below.
Excerpts from the update:
Due to ongoing shareholder requests NanoLogix is providing the following information as a short, non-comprehensive company update:
Re: The earlier mentioned project to configure the N-Assay for one of the World's two largest medical technology companies has reached its final stages. NanoLogix has received two of three development funding payments from our client for the diagnostic kit configuration for the first target bacteria. After a 90-day development process at a third-party lab, we have received the antibody serum necessary to complete the kit configuration. What remains to be done are established proprietary steps to finalize what we will provide as finished N-Assay diagnostic kits. These steps are necessary in the case of the initial bacteria chosen by our client PRECISELY because there were no existent antibodies available commercially. The entire process should be complete within a month to the point where NanoLogix then will furnish a small number of the N-Assay kits to the client for their own in-house testing. At that time NanoLogix will invoice for the third tranche payment.
Upon successful completion of testing by our client we anticipate two events to occur. These are: (1) purchase of kits (thousands) for the the first bacteria and (2) an additional, and expanded, development agreement from the client for configuration of the N-Assay for at least two additional target bacteria.
NanoLogix is also in the final N-Assay configuration stages for detection of E-coli 0157 at the request of, and for use by, a US Federal Agency. A number of the assays will be sent to the agency within three weeks for their testing evaluation.
We receive queries pertaining to the N-Assay asking why bacteria and yeast detection and identification testing results are not posted on our website. Regardless of how stunning in speed, accuracy, and sensitivity the N-Assay results are over ANY existing commercial tests, the simple answer is we are not permitted to post the results prior to publication of our research studies in a peer-reviewed scientific/medical journal.
We have been informed that doing so would constitute publication ahead of the journal. Rather than risk jeopardizing journal publication to satisfy the desires of a few over the long term interests of many, we will refrain from posting of test results until journal publication.
End of Update.
This is an exciting exciting. It doesn't even speak about the Flatpacks that we already know represent an important part of the current operating revenues for NanoLogix. But adding on to those base revenues are funds paid for the N-Assay work for "one of the two largest medical technology companies in the world" with the clearly stated expectation that there will be an expanded and ongoing relationship with that company. It is not unreasonable to consider that such a company might well be interested in acquiring the NanoLogix N-Assay technology for its own development, sales and marketing activities. I certainly hope so and am at this point quite satisfied with the state of affairs. I even bought another 20,000 shares at $.03 to add to the 40,000 I purchased some months ago. I don't even need to add shares but at these prices it is sometimes hard to resist. This isn't a "hype". We know all investments are gambles with inherent risk but this is one I am willing to take. I know I am sure not going to sell shares at this time.
I just had the chance to look at the recent update. It strikes me as quite a positive outlook but I wanted to set out several of the most exciting aspects. First, for those who have not actually read it I am copying some of the text immediately below.
Excerpts from the update:
Due to ongoing shareholder requests NanoLogix is providing the following information as a short, non-comprehensive company update:
Re: The earlier mentioned project to configure the N-Assay for one of the World's two largest medical technology companies has reached its final stages. NanoLogix has received two of three development funding payments from our client for the diagnostic kit configuration for the first target bacteria. After a 90-day development process at a third-party lab, we have received the antibody serum necessary to complete the kit configuration. What remains to be done are established proprietary steps to finalize what we will provide as finished N-Assay diagnostic kits. These steps are necessary in the case of the initial bacteria chosen by our client PRECISELY because there were no existent antibodies available commercially. The entire process should be complete within a month to the point where NanoLogix then will furnish a small number of the N-Assay kits to the client for their own in-house testing. At that time NanoLogix will invoice for the third tranche payment.
Upon successful completion of testing by our client we anticipate two events to occur. These are: (1) purchase of kits (thousands) for the the first bacteria and (2) an additional, and expanded, development agreement from the client for configuration of the N-Assay for at least two additional target bacteria.
NanoLogix is also in the final N-Assay configuration stages for detection of E-coli 0157 at the request of, and for use by, a US Federal Agency. A number of the assays will be sent to the agency within three weeks for their testing evaluation.
We receive queries pertaining to the N-Assay asking why bacteria and yeast detection and identification testing results are not posted on our website. Regardless of how stunning in speed, accuracy, and sensitivity the N-Assay results are over ANY existing commercial tests, the simple answer is we are not permitted to post the results prior to publication of our research studies in a peer-reviewed scientific/medical journal.
We have been informed that doing so would constitute publication ahead of the journal. Rather than risk jeopardizing journal publication to satisfy the desires of a few over the long term interests of many, we will refrain from posting of test results until journal publication.
End of Update.
This is an exciting exciting. It doesn't even speak about the Flatpacks that we already know represent an important part of the current operating revenues for NanoLogix. But adding on to those base revenues are funds paid for the N-Assay work for "one of the two largest medical technology companies in the world" with the clearly stated expectation that there will be an expanded and ongoing relationship with that company. It is not unreasonable to consider that such a company might well be interested in acquiring the NanoLogix N-Assay technology for its own development, sales and marketing activities. I certainly hope so and am at this point quite satisfied with the state of affairs. I even bought another 20,000 shares at $.03 to add to the 40,000 I purchased some months ago. I don't even need to add shares but at these prices it is sometimes hard to resist. This isn't a "hype". We know all investments are gambles with inherent risk but this is one I am willing to take. I know I am sure not going to sell shares at this time.
(9)
(1)